Gastrointestinal stromal tumors as an incidental finding in patients with a presumptive diagnosis of ovarian cancer.
- Author:
Mario MUNOZ
1
;
Pedro T RAMIREZ
;
Carolina ECHEVERRI
;
Luis Guillermo ALVAREZ
;
Maria Alejandra PALOMINO
;
Luis Rene PAREJA
Author Information
- Publication Type:Original Article
- Keywords: Adnexal mass; Gastrointestinal stromal tumor; Incidental finding
- MeSH: Benzamides; Diagnosis, Differential; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hepatic Encephalopathy; Humans; Imatinib Mesylate; Incidence; Incidental Findings; Medical Records; Ovarian Neoplasms; Piperazines; Postoperative Complications; Pyrimidines
- From:Journal of Gynecologic Oncology 2012;23(1):48-52
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To report the clinical presentation and oncologic outcomes of a series of patients who presented with an abdominal or pelvic mass and were diagnosed with a gastrointestinal stromal tumor (GIST). METHODS: Data were obtained on all patients who presented with an abdominal or pelvic mass between September 2007 and June 2010 and who were ultimately diagnosed with a GIST. The patients' medical records were reviewed. A literature review was also conducted. RESULTS: Six patients were identified who met the inclusion criteria. All six patients had a tumor in the intestinal tract arising from the small bowel. The mean tumor size was 12 cm (range, 6 to 22 cm). A complete resection was achieved in five of the six patients. There were no intraoperative complications; one patient had a postoperative complication. Two patients were treated with imatinib after surgery. The mean follow-up time was 32 months (range, 0.3 to 40 months). At the last follow-up, five of the six patients were without any evidence of disease. One patient died of an unrelated hepatic encephalopathy. The incidence in our institution is 3%. CONCLUSION: GISTs are uncommon; however, they should be considered in the differential diagnosis of patients presenting with an abdominal or pelvic mass.
